Recon: FDA approves Sanofi’s RSV monoclonal antibody for infants and high-risk children; Eli Lilly to acquire Versanis for $1.93B
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy